Cardiology Clinics

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from Wish List failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Cardiology Clinics

Listen for free

View show details

About this listen

A comprehensive overview of advancements in drug therapies for cardiovascular disease and related conditions, emphasizing the shift toward pharmacologic prevention and management over procedural interventions. The articles discuss new or optimized drug classes aimed at improving patient outcomes, including Angiotensin Receptor Blockers (ARBs) and direct renin inhibitors for the renin-angiotensin-aldosterone system (RAAS), new antiplatelet agents like prasugrel, and anticoagulants for acute coronary syndromes. Furthermore, the texts examine novel strategies for lipid modification, such as CETP inhibitors and extended-release niacin combined with laropiprant to mitigate flushing, and explore the role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors for managing Type 2 Diabetes Mellitus, a major cardiovascular risk factor. Finally, there is an analysis of the cardiovascular risks associated with cyclooxygenase-2 (COX-2) inhibitors (coxibs) in comparison to traditional NSAIDs.

No reviews yet